Acorda Therapeutics

Shares of Acorda Therapeutics Inc (NASDAQ: ACOR) were trading lower by 2 percent early Friday, but have since recovered most of the losses. The brief selloff occurred in reaction to the company's announcement that it will discontinue development for its Nasal Spray called Plumiaz. Plumiaz...

Acorda Therapeutics Inc (NASDAQ: ACOR) accused one of its rivals, Par Pharmaceutical, of infringing patents related to its multiple sclerosis treatment drug called Ampyra (dalfampridine) back in September, 2015. Par Pharmaceutical was seeking marketing approval from the FDA for its generic...

Acorda Therapeutics Inc (NASDAQ: ACOR), a biopharmaceutical company that develops therapies for neurological disorders, on Tuesday announced that it has acquired Biotie Therapies Oyj (ADR) (NASDAQ: BITI) for $25.60 per ADS. Biotie Therapies is a Finland-based drug development company...

Piper Jaffray has upgraded Acorda Therapeutics (NASDAQ: ACOR) from Underweight to Neutral and has raised the price target from $21 to $30.

Piper Jaffray has downgraded Acorda Therapeutics (NASDAQ: ACOR) from Neutral to Underweight and has lowered the price target from $24 to $16.

Piper Jaffray has lowered the price target on Acorda Therapeutics (NASDAQ: ACOR) from $30 to $24 and maintains its Neutral rating.

Acorda Therapeutics, Inc. (NASDAQ: ACOR) reported a solid Q3 driven by strong sales and tight exp Controls, Citigroup reports. From now on, the company said that Acorda will be profitable but demand for Ampyra will slow down after the initial pent-up demand is exhausted. “We still think this is a...

On the cusp of the 3Q10 earnings season for biotechnology, J.P. Morgan is providing an overview of the companies within the industry. This quarter, Acorda Therapeutics, Inc. (NASDAQ: ACOR) and Celgene Corporation (NASDAQ: CELG) are the leaders of the pack. “We are modestly raising our Revlimid...